Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3–5

is it significant?

Ravindra Attur Prabhu, Aswani Srinivas Mareddy, Shankar Prasad Nagaraju, Dharshan Rangaswamy, Vasudeva Guddattu

Research output: Contribution to journalArticle

Abstract

Purpose: To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3–5. Methods: We estimated plasma lactate in patients of CKD stage 3 and worse who were continuing metformin on their own prior to stopping the drug. Result: Of 40 patients included, median duration of T2DM was 60 months (interquartile range IQR 24–120). The mean serum creatinine was 309.4 ± 159.1 µmol/L and mean eGFR was 27.82 ± 12.93 mL/min/1.73 m2 with 3 (7.5%), 16 (40%), 11 (27.5%) and 10 (25%) in CKD stages 3a, 3b, 4 and 5, respectively. They were receiving metformin for a median duration of 24 months (IQR 12.5–60), an average dose of 896 ± 350 mg per day. The median of plasma lactate was 1.36 mmol/L (IQR 1.11–1.75 mmol/L) with three (7.5%) having levels above normal, two (20%) in CKD stage 5 and one (9.1%) in stage 4. Conclusion: Metformin can be safely used in CKD stage 3 and with regular measurement of plasma lactate in later stages.

Original languageEnglish
Pages (from-to)1229-1230
Number of pages2
JournalInternational Urology and Nephrology
Volume51
Issue number7
DOIs
Publication statusPublished - 01-07-2019

Fingerprint

Lactic Acidosis
Metformin
Chronic Renal Insufficiency
Type 2 Diabetes Mellitus
Lactic Acid
Creatinine
Cohort Studies
Serum
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Nephrology
  • Urology

Cite this

@article{dc16b328132e468ba4cd041816c1fe5a,
title = "Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3–5: is it significant?",
abstract = "Purpose: To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3–5. Methods: We estimated plasma lactate in patients of CKD stage 3 and worse who were continuing metformin on their own prior to stopping the drug. Result: Of 40 patients included, median duration of T2DM was 60 months (interquartile range IQR 24–120). The mean serum creatinine was 309.4 ± 159.1 µmol/L and mean eGFR was 27.82 ± 12.93 mL/min/1.73 m2 with 3 (7.5{\%}), 16 (40{\%}), 11 (27.5{\%}) and 10 (25{\%}) in CKD stages 3a, 3b, 4 and 5, respectively. They were receiving metformin for a median duration of 24 months (IQR 12.5–60), an average dose of 896 ± 350 mg per day. The median of plasma lactate was 1.36 mmol/L (IQR 1.11–1.75 mmol/L) with three (7.5{\%}) having levels above normal, two (20{\%}) in CKD stage 5 and one (9.1{\%}) in stage 4. Conclusion: Metformin can be safely used in CKD stage 3 and with regular measurement of plasma lactate in later stages.",
author = "Prabhu, {Ravindra Attur} and Mareddy, {Aswani Srinivas} and Nagaraju, {Shankar Prasad} and Dharshan Rangaswamy and Vasudeva Guddattu",
year = "2019",
month = "7",
day = "1",
doi = "10.1007/s11255-019-02136-y",
language = "English",
volume = "51",
pages = "1229--1230",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "7",

}

Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3–5 : is it significant? / Prabhu, Ravindra Attur; Mareddy, Aswani Srinivas; Nagaraju, Shankar Prasad; Rangaswamy, Dharshan; Guddattu, Vasudeva.

In: International Urology and Nephrology, Vol. 51, No. 7, 01.07.2019, p. 1229-1230.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lactic acidosis due to metformin in type 2 diabetes mellitus and chronic kidney disease stage 3–5

T2 - is it significant?

AU - Prabhu, Ravindra Attur

AU - Mareddy, Aswani Srinivas

AU - Nagaraju, Shankar Prasad

AU - Rangaswamy, Dharshan

AU - Guddattu, Vasudeva

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Purpose: To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3–5. Methods: We estimated plasma lactate in patients of CKD stage 3 and worse who were continuing metformin on their own prior to stopping the drug. Result: Of 40 patients included, median duration of T2DM was 60 months (interquartile range IQR 24–120). The mean serum creatinine was 309.4 ± 159.1 µmol/L and mean eGFR was 27.82 ± 12.93 mL/min/1.73 m2 with 3 (7.5%), 16 (40%), 11 (27.5%) and 10 (25%) in CKD stages 3a, 3b, 4 and 5, respectively. They were receiving metformin for a median duration of 24 months (IQR 12.5–60), an average dose of 896 ± 350 mg per day. The median of plasma lactate was 1.36 mmol/L (IQR 1.11–1.75 mmol/L) with three (7.5%) having levels above normal, two (20%) in CKD stage 5 and one (9.1%) in stage 4. Conclusion: Metformin can be safely used in CKD stage 3 and with regular measurement of plasma lactate in later stages.

AB - Purpose: To study the incidence of lactic acidosis due to metformin in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) stage 3–5. Methods: We estimated plasma lactate in patients of CKD stage 3 and worse who were continuing metformin on their own prior to stopping the drug. Result: Of 40 patients included, median duration of T2DM was 60 months (interquartile range IQR 24–120). The mean serum creatinine was 309.4 ± 159.1 µmol/L and mean eGFR was 27.82 ± 12.93 mL/min/1.73 m2 with 3 (7.5%), 16 (40%), 11 (27.5%) and 10 (25%) in CKD stages 3a, 3b, 4 and 5, respectively. They were receiving metformin for a median duration of 24 months (IQR 12.5–60), an average dose of 896 ± 350 mg per day. The median of plasma lactate was 1.36 mmol/L (IQR 1.11–1.75 mmol/L) with three (7.5%) having levels above normal, two (20%) in CKD stage 5 and one (9.1%) in stage 4. Conclusion: Metformin can be safely used in CKD stage 3 and with regular measurement of plasma lactate in later stages.

UR - http://www.scopus.com/inward/record.url?scp=85064274219&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064274219&partnerID=8YFLogxK

U2 - 10.1007/s11255-019-02136-y

DO - 10.1007/s11255-019-02136-y

M3 - Article

VL - 51

SP - 1229

EP - 1230

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 7

ER -